ESR1 and breast cancer: Saxena et al. [18] reported that in combination with other factors (i.e. age, treatment, grade, tumor size and receptor status) LNR did not provide any added prognostic value for south east Asian breast cancer patients in comparison to pN except for ≥60 year old women with ER negative or grade 3 tumors.